“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Treatment of schizophrenia with ergot derivatives

Treatment of schizophrenia with ergot derivatives 213 66 66 3 3 C. A. Tamminga M. H. Schaffer Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke National Institutes of Health 20205 Bethesda MD USA Manteno Mental Health Center Manteno Illinois USA Department of Psychiatry University of Chicago 60637 Chicago Ill. USA Abstract Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals
Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.